Viking Therapeutics closed at $27.97 on Nov 4, up 7.21%, 33.6% below its 52-week closing high. Volume of 4.4M shares was 0.91× its 20-day average (close to normal).
Split-adjusted performance: -1.4% over one month, -13.4% over six months, -22.3% over one year.
Short interest was 25.5M shares at the Oct 15 settlement, down 1.5% from the prior report (22.8% of float, 4.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| VKTXViking Therapeutics | $27.97 | +7.21% | −13.4% | — | — | — | $3.57B | |
| OGNOrganon & | $13.83 | −0.14% | +3.1% | −1.7% | 10.4% | 17.1 | $3.63B | Compare |
| DYNDyne Therapeutics | $18.54 | +2.71% | −1.6% | — | — | — | $3.46B | Compare |
| ELVNEnliven Therapeutics | $47.25 | +5.40% | +14.7% | — | — | — | $3.46B | Compare |
| AMLXAmylyx Pharmaceuticals | $29.40 | +0.68% | +83.1% | — | — | — | $3.69B | Compare |
| IRONDisc Medicine | $83.28 | +2.61% | +21.3% | — | — | — | $3.70B | Compare |
| ACADAcadia Pharmaceuticals | $21.47 | +4.38% | 0.0% | +16.4% | 10.2% | 9.7 | $3.70B | Compare |
| PBLSParabilis Medicines | $30.36 | +3.79% | — | — | −45239.9% | — | $3.75B | Compare |
| XENEXenon Pharmaceuticals | $39.19 | +2.51% | −33.1% | — | — | — | $3.80B | Compare |
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
